drugset / Trial / NCT00726596
Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
Phase 2
Completed
64 enrolled
Rutgers, The State University of New Jersey
National Cancer Institute (NCI) · collabRutgers Cancer Institute of New Jersey · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well hydroxychloroquine works in treating patients with previously treated prostate cancer. Autophagy destroys proteins and other substances in cells and may be used by prostate cancer cells to survive. Hydroxychloroquine, which blocks autophagy, may slow the growth of and possibly kill prostate cancer cells.
Timeline
- Start
- 2008-08
- Primary completion
- 2014-02
- Completion
- 2018-01
Outcome
Missed primary endpoint
registry analysis (superiority test); Cohort A. Hydroxychloroquine (200mg Bid) vs Cohort B. Hydroxychloroquine (200mg Tid); p = .6789; t-test, 1 sided NCT00726596 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxychloroquine | Small molecule | 400 mg | — |
| Subject | Hydroxychloroquine | Small molecule | 600 mg | — |